Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...
Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...
Injection 8 mg for treating macular edema due to retinal vein occlusion (RVO). This includes patients with central, branch, and hemiretinal vein occlusions. The data from this trial will support a ...
Researchers at Australia's WEHI (Walter and Eliza Hall Institute) medical research center applied AI analysis to over 50,000 ...
A color vision test shows good correlation with cone and cone-rod dystrophy biomarkers and may offer a cost-effective replacement for ERG.
Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...
Rights Mar 17, 2011 Mar 18, 2011 Jul 29, 2010 Rights ratio: 3 share for every 5 held at a price of Rs 103.0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback